Operational Costs Compared: SG&A Analysis of Novartis AG and Pfizer Inc.

A Decade of SG&A: Novartis AG vs. Pfizer Inc.

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Novartis AG and Pfizer Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Novartis AG's SG&A expenses peaked in 2018, reaching approximately 16% higher than their 2023 figures. Meanwhile, Pfizer Inc. showed a more stable trajectory, with a notable dip in 2020, coinciding with global economic shifts. By 2023, Pfizer's SG&A expenses rebounded, surpassing Novartis by around 18%. This analysis highlights the strategic financial maneuvers of these pharmaceutical giants, reflecting their adaptability in a competitive market. As the industry continues to face challenges, understanding these financial patterns offers valuable insights into corporate strategies and market positioning.